Brainstorm Cell Therapeutics Inc. announced that Dr. Stacy Lindborg stepping down from the role of Co-CEO, effective as of May 9, 2024 and will remain with BrainStorm as a member of its Board of Directors. Dr. Lindborg served as the Company?s Co-Chief Executive Officer from January 2023 to April 2024. Prior to this, from June 2020 to January 2023, Dr. Lindborg served as Executive Vice President and Chief Development Officer. She currently serves on the board of directors of Imunon Inc. Dr. Lindborg previously served at Biogen Inc. (?Biogen?) from 2012 to 2020, where she was most recently Vice President, Analytics and Data Science. She also served on the R&D governance team during a time of significant growth for Biogen, and was active in guiding the firm?s long-term vision for growth through analytics and by stimulating innovative development platforms to increase productivity. Prior to her role at Biogen, Dr. Lindborg worked at Eli Lilly & Company, where she held positions of increasing responsibility. In her role as the Head of R&D strategy, she was responsible for characterizing the productivity of the portfolio and driving key R&D strategy projects including the annual R&D Long-Range Plan. Additionally, she was Leader of Zyprexa Product Management in which she was responsible for R&D, Commercial and Manufacturing plans. Dr. Lindborg holds a Ph.D. in statistics from Baylor University.

.